Mark Wildgust
Mark Wildgust is an executive in the oncology division of Johnson & Johnson, a company that collaborated with Legend Biotech to develop CAR-T therapy for multiple myeloma. He played a pivotal role in validating the treatment's effectiveness by personally overseeing investigations into its claims and helping to bring the therapy to patients who had exhausted other options.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Ireland:
Mark Wildgust, an executive in the oncology section of Johnson & Johnson, discusses the collaboration with Legend Biotech.
7